Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 04, 2015 9:46 AM ET


Company Overview of Trius Therapeutics, Inc.

Company Overview

Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious infections. It develops tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections; and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also develops GyrB/ParE, which are under preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such...

6310 Nancy Ridge Drive

Suite 105

San Diego, CA 92121

United States

Founded in 2004

94 Employees





Key Executives for Trius Therapeutics, Inc.

Chief Executive Officer, President and Executive Director
Age: 60
Founder and Chief Scientific Officer
Age: 59
Founder and Director of Drug Discovery
Compensation as of Fiscal Year 2015.

Trius Therapeutics, Inc. Key Developments

Trius Therapeutics Wins $19,758,137 Federal Contract

Trius Therapeutics, San Diego, won a $19,758,137 federal contract from the U.S. Department of Health and Human Services' National Institutes of Health, Bethesda, Md., for the development of therapeutic medical countermeasures for biodefense and emerging infectious diseases.

Trius Therapeutics, Inc.(NasdaqGM:TSRX) dropped from Russell 2000 Index

Trius Therapeutics, Inc. will be removed from Russell 2000 Index.

Trius Therapeutics, Inc.(NasdaqGM:TSRX) dropped from Russell 3000 Index

Trius Therapeutics, Inc. will be removed from Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
ParentPlus, LLC United States
Rinat Neuroscience Corp. United States
Alvogen, Inc. United States
NutraGenomics, Inc. United States
AxCell Biosciences Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Trius Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at